Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?
Mohamad Abou Chakra(University of Iowa Health Care), Michael A. O’Donnell(University of Iowa Health Care), Igor Duquesne(Hôpital Cochin), Ian M. McElree(Vanderbilt University Medical Center), Michaël Peyromaure(Hôpital Cochin), Vignesh T. Packiam(Rutgers, The State University of New Jersey)
Cited by 18
Related Papers
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer
|JAMA Network Open|2023|116
Collecting Duct Carcinoma of the Kidney: A Clinicopathological Study Of 9 Cases
|The Journal of Urology|2003|94
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer
|The Journal of Urology|2022|71
Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer
|Urologic Oncology Seminars and Original Investigations|2022|59